The post How High Can Hyperliquid Price Go in Feb 2026? appeared on BitcoinEthereumNews.com. Hyperliquid price has experienced a notable surge recently, seeing The post How High Can Hyperliquid Price Go in Feb 2026? appeared on BitcoinEthereumNews.com. Hyperliquid price has experienced a notable surge recently, seeing

How High Can Hyperliquid Price Go in Feb 2026?

Hyperliquid price has experienced a notable surge recently, seeing impressive gains over the past 24 hours. 

The HYPE surged by 20%, making it one of the top gainers in the crypto market. HYPE gained more than 60% in the last week, outdoing Bitcoin, Ethereum, and other top cryptocurrencies.

The overall crypto marketcap ha seen a recovery with a 2.06% rise. Additionally, HYPE price has surged by over 50 % over the past week, to $34.57. This is a price improvement that is attributed to the surge in the site as more traders join the expanding market.

Why Is Hyperliquid Price Up?

Hyperliquid’s price surge is driven by multiple factors. A major catalyst is the platform’s recent growth and rising trading activity.

Originally focused on crypto perpetual contracts, Hyperliquid expanded to tokenized trading of commodities, stocks, equity indices, and fiat currencies through its HIP-3 upgrade.

The results of this huge growth were impressive: more than 1 billion Open Interest and a total trading volume of 25 billion and fees of 3 million in only three months. This expansion has brought much attention of the investors, and it has caused a rise in speculative interest, particularly in the derivatives market.

Source: Coinglass

A key factor in the price increase is the platform’s token-burning mechanism. It purchases protocol fees as high as 97% and burns out HYPE tokens. The more the trading volume, the more the rate of burning, and the stronger the demand, raising the price of the token.

The boom in commodity exchange, especially silver, has been playing a great role in the generation of fees on the platform. This growth in volume has also increased the demand for HYPE, thus helping to increase its growth.

The price of HYPE is expected to remain on its bullish trend as the market recovers and Hyperliquid develops its tokenized trading offerings. Investor interest and favorable technical indicators suggest further growth.

Will Hyperliquid Price Rally Above $50 in Feb 2026?

HYPE price has risen by 20% in the last 24 hours, which indicates a high upward trend. The cryptocurrency has experienced a massive momentum, as it was steadily on the rise following a period of consolidation.

The RSI (Relative Strength Index) currently reads 82, placing it well into overbought territory. This implies that it may move to a short-term decline or consolidation unless new buyers are attracted actively.

The MACD (Moving Average Convergence Divergence is still bullish when the MACD line is above the signal line.

Immediate support lies at $30.00, a good psychological support, and technical support, where the buyers might retrace. Immediate resistance lies at $35.00, a local barrier, and the former high before a possible breakout.

Source: HYPE/USDT 4-hour chart: Tradingview

If the bullish trend continues, the Hype long-term prediction could test new highs in the near future, with $35.00 and $40 and $50 as potential targets.

Source: https://coingape.com/markets/how-high-can-hyperliquid-price-go-in-feb-2026/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26